Stay updated with breaking news from Andreas Bergmann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Though scientists don’t yet know much about it, a newly described process called erebosis might have profound implications for how the gut maintains itself.
A multi-centre study led by the University Hospital Hamburg-Eppendorf (UKE) is evaluating one of the first personalised approaches for moderate to sever...
A multi-center study led by UKE is evaluating one of the first personalized approaches for moderate to severe COVID-19 patients.The innovative biomarkers bio-ADM and DPP3 are guiding the enrollment of
Issuer: 4TEEN4 Pharmaceuticals GmbH / Key word(s): Study 11.04.2022 / 11:00 The issuer is solely responsible for the content of this announcement. Dipeptidyl Peptidase 3 release is
11.04.2022 Biomarker-guided trial led by University Hospital Hamburg-Eppendorf (UKE) opens new avenues for personalized medicine in COVID-19 | bio-ADM | biomarkers | COVID-19 | DPP3